Lotus Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|
| LP757 | Advanced renal cell carcinoma and other solid tumors | NDA filing |
| FYB206 | PD‑1 solid cancer immunotherapy (Keytruda biosimilar) | Phase 3 |
| SLX-100 | Oncology (specific indication undisclosed) | Phase 2 |